{"entity":{"type":"insider","cik":"0001520265","url":"/insider/0001520265","json_url":"/insider/0001520265.json","name":"Fitzpatrick Mark J.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":6,"first":"2012-03-26","last":"2018-12-21","span_basis":"filed_date"},"name_variants":[{"name":"Fitzpatrick Mark J.","source":"filing","n_filings":6,"first_seen":"2012-03-26","last_seen":"2018-12-21"}],"transactions":[{"id":6805370,"accession":"0001209191-18-063832","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-063832","line_url":"/filing/0001209191-18-063832#line-1","is_derivative":false,"issuer_cik":"0001339469","issuer_name":"CHIASMA, INC","issuer_ticker":"CHMA","issuer_name_source":null,"issuer_url":"/issuer/0001339469","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9612.0,"shares_display":"9,612","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":24030.0,"total_display":"24,030.00","total_whole":"24,030","shares_owned_after":9612.0,"shares_owned_after_display":"9,612","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-20","filed_date":"2018-12-21","scope":"insider"},{"id":6913393,"accession":"0001209191-14-053601","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-053601","line_url":"/filing/0001209191-14-053601#line-1","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1150.0,"shares_display":"1,150","price_per_share":30.64,"price_display":"30.64","price_state":"stated","total_value":35236.0,"total_display":"35,236.00","total_whole":"35,236","shares_owned_after":9500.0,"shares_owned_after_display":"9,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-19","filed_date":"2014-08-20","scope":"insider"},{"id":6586717,"accession":"0001209191-14-009634","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-009634","line_url":"/filing/0001209191-14-009634","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":62.6058,"price_display":"62.61","price_state":"stated","total_value":469543.5,"total_display":"469,543.50","total_whole":"469,544","shares_owned_after":10050.0,"shares_owned_after_display":"10,050","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-10","filed_date":"2014-02-12","scope":"insider","n_lines":4},{"id":4978304,"accession":"0001181431-13-058808","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001181431-13-058808","line_url":"/filing/0001181431-13-058808","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":79.0438284,"price_display":"79.04","price_state":"stated","total_value":592828.713,"total_display":"592,828.71","total_whole":"592,829","shares_owned_after":4800.0,"shares_owned_after_display":"4,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-11","filed_date":"2013-11-13","scope":"insider","n_lines":6},{"id":5109852,"accession":"0001181431-13-045320","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-13-045320","line_url":"/filing/0001181431-13-045320","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":93.44209013333334,"price_display":"93.44","price_state":"stated","total_value":700815.676,"total_display":"700,815.68","total_whole":"700,816","shares_owned_after":1088.0,"shares_owned_after_display":"1,088","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-14","filed_date":"2013-08-16","scope":"insider","n_lines":3},{"id":2621848,"accession":"0001181431-12-019350","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-019350","line_url":"/filing/0001181431-12-019350","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001520265","owner_name":"Fitzpatrick Mark J.","owner_display_name":"Fitzpatrick Mark J.","owner_url":"/insider/0001520265","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":14.1524,"price_display":"14.15","price_state":"stated","total_value":7076.2,"total_display":"7,076.20","total_whole":"7,076","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-23","filed_date":"2012-03-26","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":13,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001339469","name":"CHIASMA, INC","url":"/issuer/0001339469","role":"Director, Officer (President and CEO)","n_filings":1,"first_seen":"2018-12-21","last_seen":"2018-12-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001338042","name":"Aegerion Pharmaceuticals, Inc.","url":"/issuer/0001338042","role":"Officer (Chief Financial Officer)","n_filings":5,"first_seen":"2012-03-26","last_seen":"2014-08-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001520265","retrieved_at":"2026-08-22T21:45:48+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}